Standard Yervoy Dosing Schedule
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, follows a fixed induction regimen of 3 mg/kg intravenously every 3 weeks for 4 doses, totaling about 3 months.[1] This spans 9 weeks from first to last dose.
Duration in Combination Therapies
When combined with Opdivo (nivolumab), the schedule adjusts: Yervoy at 1 mg/kg every 6 weeks for 4 doses (about 4.5 months), while Opdivo continues longer.[1][2] For adjuvant melanoma treatment, it's 10 mg/kg every 3 weeks for 4 doses, then every 12 weeks for up to 3 years total.[1]
What Happens After Induction?
No further Yervoy is given post-induction unless in extended adjuvant settings. Opdivo may continue up to 2 years in combos, based on response and guidelines.[2] Treatment stops early for progression, toxicity, or completion.
How Long Until Effects Kick In?
Responses can start within weeks but often take 2-3 months, with full benefits assessed via scans after induction.[3]
Why Does Duration Vary?
Dosing depends on indication (e.g., metastatic melanoma vs. renal cell carcinoma), weight-based mg/kg, and combo status. Oncologists tailor based on NCCN guidelines and patient tolerance.[1][2]
Common Side Effects During Treatment
Immune-related issues like colitis, hepatitis, or rash peak during/after induction, sometimes requiring pauses or steroids.[3] Monitoring continues post-treatment.
[1]: Yervoy Prescribing Information (Bristol Myers Squibb)
[2]: NCCN Guidelines for Melanoma (Version 2.2024)
[3]: FDA Label for Yervoy